Key result
Moxonidine lowers blood pressure and improves metabolic parameters and body mass in metabolic syndrome.
Why the study?
The MERSY study was conducted to assess the long-term safety and efficiency of the I2-imidazolin receptor agonist moxonidine in patients with arterial hypertension and metabolic syndrome.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for moxonidine in hypertension with metabolic syndrome; prospective trials needed before clinical adoption.
The multicenter research MERSY (Moxonidine Efficacy on blood pressure Reduction revealed in a metabolic SYndrome population) finished in 2008 was devoted to an assessment of long-term safety and efficiency of agonist I2-imidazolin receptors – moxonidine in patients with arterial hypertension and metabolic syndrome (in the general group and in advance defined subgroup of patients in a postmenopause). In 2013 final international results of the research MERSY which showed high antihypertensive activity of moxonidine, and also its positive influence on metabolic parameters and mass of a body were published.
No takes yet. Share an insight, caveat, or question.
Валерьевна et al. (2013) conducted a review in Arterial hypertension and metabolic syndrome. Moxonidine was evaluated on Blood pressure reduction, long-term safety, metabolic parameters, and body mass. Moxonidine demonstrated high antihypertensive activity and a positive influence on metabolic parameters and body mass in patients with hypertension and metabolic syndrome in the MERSY study.
Synapse has enriched 10 related papers. Consider them for comparative context: